Wells Fargo & Company Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $20.00

Viridian Therapeutics (NASDAQ:VRDN) had its price objective cut by research analysts at Wells Fargo & Company from $29.00 to $20.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 4.44% from the company’s previous close.

Other research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen downgraded Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. UBS Group began coverage on Viridian Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 price objective for the company. Needham & Company LLC cut their target price on Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Evercore reiterated an “outperform” rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 20th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.21.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN opened at $19.15 on Tuesday. Viridian Therapeutics has a twelve month low of $9.90 and a twelve month high of $34.29. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08. The firm has a 50-day moving average of $28.90 and a two-hundred day moving average of $27.83. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -5.82 and a beta of 1.16.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $15.75 million. As a group, analysts expect that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Viridian Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VRDN. Avoro Capital Advisors LLC acquired a new stake in Viridian Therapeutics during the 4th quarter valued at $46,680,000. Seven Fleet Capital Management LP acquired a new stake in shares of Viridian Therapeutics in the fourth quarter worth $456,000. Virtu Financial LLC acquired a new stake in shares of Viridian Therapeutics in the fourth quarter worth $531,000. Invesco Ltd. grew its holdings in shares of Viridian Therapeutics by 127.1% during the fourth quarter. Invesco Ltd. now owns 183,468 shares of the company’s stock valued at $5,710,000 after buying an additional 102,676 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Viridian Therapeutics during the fourth quarter valued at $1,464,000.

Key Headlines Impacting Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Company reported positive topline results from the Elegrobart Phase 3 REVEAL‑1 trial in active thyroid eye disease — the clinical readout is a fundamental positive for long‑term drug value and commercial potential. Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and set a $22 target while revising Q1–Q4 and FY2026 EPS estimates (small mix of raises and cuts) — shows continued analyst support but revised modeling reflects higher near‑term costs/assumptions. HC Wainwright estimate and rating note
• Neutral Sentiment: Recent intraday swings included a sharp bounce the prior session (Zacks noted a 5.6% jump on higher‑than‑average volume), highlighting that VRDN is trading on headline events and momentum as much as fundamentals. Viridian Therapeutics (VRDN) Soars 5.6%
• Negative Sentiment: Shares plunged pre‑market on headlines that followed the Phase 3 disclosure (market reaction suggests investors were disappointed by details beyond topline, or that expectations were higher), triggering heavy selling and volatility. VRDN stock plummeted 41% pre-market today
• Negative Sentiment: Multiple firms trimmed price targets (Goldman Sachs to $36, Wells Fargo to $20 with an equal‑weight, Wedbush to $37, HC Wainwright down to $22) — these cuts signal reduced near‑term upside in sell‑side models and likely contributed to downward pressure. Broker price target updates
• Negative Sentiment: Several news outlets highlighted that shares fell despite the positive topline, suggesting investor concerns about safety details, subgroup results, magnitude of benefit, or commercial assumptions — expect continued headline‑driven trading until full data and guidance are clarified. Viridian Therapeutics stock tumbles despite trial success

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.